Table 2. Results of Kaplan–Meier overall survival and disease-free survival analyses for all patients, patients in the p53 mutant and in the p53 wild-type cohorts.

		Survival						Disease free
		All patients		p53 m patients		p53WT patients		All patients		p53 m patients		p53WT patients
	Dep. group	χ 2	P	χ 2	P	χ 2	P	χ 2	P	χ 2	P	χ 2	P
p53 mutation (vs WT)	All	21.27	<0.0001	—	—	—	—	23.31	<0.0001	—	—	—	—
	1–9	9.96	0.002	—	—	—	—	12.10	0.001	—	—	—	—
	10	8.01	0.005	—	—	—	—	9.18	0.002	—	—	—	—
Tumour grade (1–2 vs 3)	All	22.33	<0.0001	2.95a	0.086a	9.23	0.002	17.38	<0.0001	3.22a	0.073a	2.75	0.097
	1–9	18.81	<0.0001	3.55a	0.059a	9.58	0.002	13.96	0.0002	3.94 a	0.047 a	2.97	0.085
	10	1.51	0.219	0.01a	0.937a	N/Ab	N/Ab	1.31	0.252	8.20 a	0.004 a	N/Ab	N/Ab
Tumour size (<2 cm vs ⩾2 cm)	All	10.13	0.001	0.32	0.574	14.95	0.0001	8.06	0.005	2.20	0.138	5.11	0.024
	1–9	11.01	0.001	0.28	0.596	14.32	0.0002	8.25	0.004	2.30	0.130	4.75	0.029
	10	1.08	0.298	1.07	0.300	N/Ab	N/Ab	2.05	0.152	9.54	0.002	N/Ab	N/Ab
ER (+ vs −)	All	31.65	<0.0001	5.75	0.017	13.79	0.0002	25.06	<0.0001	5.38	0.020	6.54	0.011
	1–9	27.83	<0.0001	5.81	0.016	13.66	0.0002	22.71	<0.0001	6.80	0.009	6.47	0.011
	10	3.40	0.065	0.97	0.326	N/Ab	N/Ab	1.80	0.180	0.14	0.704	N/Ab	N/Ab
HER2 (+ vs −)	All	3.38	0.066	0.24	0.626	4.62	0.032	6.24	0.013	0.67	0.414	0.74	0.389
	1–9	5.65	0.017	0.15	0.702	8.71	0.003	8.33	0.004	0.59	0.441	2.61	0.106
	10	1.67	0.197	0.33	0.563	N/Ab	N/Ab	0.91	0.339	0.44	0.507	N/Ab	N/Ab
Triple negative (yes vs no)	All	16.72	<0.0001	5.21	0.022	3.80	0.051	12.52	0.0004	3.82	0.051	2.52	0.112
	1–9	13.41	0.0003	4.92	0.027	3.39	0.066	10.29	0.001	4.44	0.035	2.15	0.142
	10	2.48	0.115	0.08	0.774	N/Ab,c	N/Ab,c	1.32	0.250	0.03	0.854	N/Ab,c	N/Ab,c
Nodal status (+ vs −)	All	19.14	<0.0001	5.33	0.021	9.55	0.002	15.92	<0.0001	11.90	0.0006	2.07	0.150
	1–9	16.96	<0.0001	4.72	0.030	9.21	0.002	12.42	0.0004	10.46	0.001	1.87	0.171
	10	3.08	0.079	1.35	0.244	N/Ab	N/Ab	4.62	0.032	2.39	0.122	N/Ab	N/Ab

Abbreviations: ER=oestrogen receptor; WT=wild type.

Results are also detailed by deprivation groups 1–9 and 10.

^aThere were no p53 mutation patients, who had Grade 1 tumours.

^bAll patients in deprivation group 10 without a p53 mutation survived and remained disease free.

^cAll patients in deprivation group 10 without a p53 mutation were free of triple-negative tumours. All analyses have one degree of freedom, and statistically significant results are highlighted in bold type.